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ABSTRACT
Background: The therapeutic use of Kampo medicine, Sho-seiryu-to (SST) in allergic disorders is well
known. As histamine plays a central role in allergic diseases, it is possible that SST affects the allergy-related
histamine signaling. In this study, we investigated the effect of SST on allergy-related histamine signaling in the
nasal mucosa of toluene 2, 4-diisocyanate (TDI)-sensitized nasal allergy model rats.
Methods: Six-week-old male, Brown Norway rats were sensitized for 2 weeks with 10 μl of 10% TDI, and after
a 1 week interval, provocation was initiated with the same amount of TDI. SST (0.6 grat) was given orally 1
hour before TDI treatment began for a period of 3 weeks. Nasal symptoms were scored for 10 minutes immedi-
ately after TDI-provocation. The genes expression in nasal mucosa was determined using real-time quantita-
tive RT-PCR.
Results: SST significantly suppressed TDI-induced nasal allergy-like symptoms. TDI provocation showed a
significant up-regulation of histamine H1 receptor (H1R) and histidine decarboxylase (HDC) gene expressions.
Prolonged pre-treatment of SST significantly suppressed the mRNA levels of H1R and HDC that was up-
regulated by TDI. SST also suppressed TDI-induced interleukin (IL)-4 and IL-5 mRNA elevation. However, SST
showed no significant effect for TDI-induced mRNA elevation of IL-13.
Conclusions: These results demonstrate that SST alleviates nasal symptoms by the inhibition of histamine
signaling through suppression of TDI-induced H1R and HDC gene up-regulation. SST also suppresses cy-
tokine signaling through suppression of IL-4 and IL-5 gene expression. Suppression of histamine signaling may
be a novel mechanism of SST in preventing allergic diseases.
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INTRODUCTION
The prevalence of allergic diseases has increased sig-
nificantly around the world today1,2 where 1 in every
5 children develops an allergy during their childhood.
Thus, the satisfactory diagnosis and treatment of al-
lergy is still a challenge in modern medicine. Syn-
thetic as well as natural resources are being investi-
gated for this purpose and the potent therapeutic
plants mentioned in ancient literature, as well as tra-
ditional medicine, can be a credible area to be ex-
plored for the establishment of improved therapy for
allergic conditions.
Histamine is a key biogenic amine responsible for
allergy and inflammatory reactions mediated through
4 distinct receptors such as H1, H2, H3 and H4 recep-
tors.3,4 Among them, the histamine H1 receptor
(H1R) plays an essential role in the development of
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allergic pathogenesis. In eukaryotes, histidine decar-
boxylase (HDC) is the sole enzyme responsible for
synthesizing histamine and consequently a crucial
regulatory step for histamine signaling. The allergic
reaction is also characterized by a disruption of Th1
Th2 balance toward a pronounced Th2 profile. Th2
cytokines, especially interleukin (IL)-4, IL-5 and IL-
13, may play a vital role in the development and main-
tenance of allergic responses.5-9 Increasing experi-
mental evidence suggest the existence and impor-
tance of the role of the histamine-cytokine network in
allergic inflammation, in which histamine influences
the expression and actions of several cytokines and
some cytokines modulate the production and release
of histamine.10-13
Toluene 2,4-diisocyanate (TDI) is a recognized hu-
man irritant and one of the leading causes of occupa-
tional allergic diseases in industrialized countries.14,15
We previously reported that TDI-sensitized animals
share several features of nasal allergic diseases, in-
cluding elevation of H1R mRNA levels and its protein
level,15 increase in HDC mRNA levels, HDC activity
and histamine content.16 TDI also induces respiratory
allergy with Th2-dominated responses such as in-
crease in the levels of IL-4, IL-5 and IL-13, total and
specific serum IgE levels, airway inflammation char-
acterized by activated CD4+ T cells, eosinophils and
mast cells, and airway remodeling.17-20
Sho-seiryu-to (SST), also known as Xiao-quing-
long-tang in China and So-cheong-ryong-tang in Ko-
rea, is a traditional Kampo medicine that has been
used as a natural cure for allergy symptoms for hun-
dreds of years in Asian countries. Several studies
have been conducted recently to evaluate its effect
clinically and experimentally, as well as its pharma-
cological properties. SST showed suppressive effects
on histamine release from rat peritoneal mast cells,21
reduced serum IgE levels in allergic rhinitis pa-
tients,22,23 repressed allergen-induced bronchial in-
flammation in mite-sensitized mice,24 modulation of
Th1- andor Th2-cytokine in CD4+ T cells in mice.25-27
However, the therapeutic mechanisms of this Kampo
medicine are still unclear.
In the present study, we investigated the effect of
SST on allergic symptoms as well as on the expres-
sions of the allergy-sensitive genes involved in hista-
mine signaling such as H1R and HDC using TDI-
sensitized nasal allergy model rats. We also investi-
gated the effect of SST on TDI-induced elevation of
the Th2-cytokine mRNAs including IL-4, IL-5, and IL-
13.
METHODS
PREPARATION AND ADMINISTRATION OF SST
Thirty-six grams of SST (Tsumura & Co., Tokyo, Ja-
pan) was added to 500 ml of distilled water and left to
stand for 1 hour at room temperature. The SST sus-
pension was then boiled for 2 hours filtered twice to
remove insoluble materials, and. the extract was con-
centrated to 126 ml. The rats were orally given the
extract once a day at a dosage of 0.6 grat for 3
weeks, 1 hour before TDI application. This dosage
corresponds to that of the original SST used for ex-
traction. In literature, Sakaguchi et al. used 100 mg
kg−1000 mgkg SST28 and Umesato et al. adminis-
tered SST orally once a day at a dosage of 1 gkg.29
Therefore the amount of SST used in this study is
comparable with the amount that has been used in
previous studies.
TDI SENSITIZATION AND PROVOCATION
We used 6-week-old male, Brown, Norway rats,
weighing 200−250 g (Japan SLC, Hamamatsu, Japan)
for the present study. Rats were given free access to
water and food, and kept in a room where constant
temperature (25 ± 2)℃ and humidity (55 ± 10%) were
maintained, and a 1212 hour lightdark cycle was
kept. Rats were divided into 3 groups each containing
4 rats. Sensitization by TDI was performed by the
method previously reported.16 In brief, 10 μl of 10%
solution of TDI (Wako Chemical, Tokyo, Japan) in
ethyl acetate (Wako) was applied bilaterally in the na-
sal vestibules once a day for 5 consecutive days. This
sensitization procedure was then repeated after a 2-
day interval. Nine days after the second sensitization,
10 μl of 10% TDI solution was applied again to the na-
sal vestibules to provoke nasal allergy-like behaviors
in the TDI-sensitized rats. Nasal allergy-like behavior
was measured by counting the number of sneezes
during the 10 minutes immediately after TDI provo-
cation. Among the 3 groups, rats in groups 2 and 3
were sensitized with TDI solution. SST was given
orally to each rat in group 3. Group 1 was treated with
ethyl acetate and phosphate buffer as a control (Fig.
1). All animal experiments were approved by the
Ethical Committee for Animal Studies of School of
Medicine, the University of Tokushima, Japan.
MEASUREMENT OF mRNAs BY REAL-TIME
QUANTITATIVE REVERSE TRANSCRIPTION PO-
LYMERASE CHAIN REACTION (REAL-TIME RT-
PCR)
Rats were sacrificed 4 hours after provocation, and
nasal mucosa was removed from the nasal septum.
Samples were collected in RNAlaterⓇ (Applied Bio-
systems, Foster City, CA) and stored at －80℃ until
used. Total RNA was isolated using TRIzol Reagent
(Invitrogen, Carlsbad, CA, USA) as reported previ-
ously.16 In short, nasal mucosa was homogenized us-
ing a Polytron (Model PT-K; Kinematica AG, Littau
Luzern, Switzerland) in 10 volumes of ice-cold TRIzol
reagent until completely disrupted. The homogenates
were mixed with chloroform and centrifuged at
15,000 rpm for 15 minutes at 4℃. The RNA was pre-
cipitated by addition of isopropanol in the aqueous
phase and centrifuged. The RNA pellet was washed
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Fig. 1 Protocol for TDI sensitization and provocation. Rats were sensitized with 10 μl of 
10% TDI in ethyl acetate for 5 consecutive days. This was repeated after a 2- day interval. 
Provocation was initiated 9 days after the last sensitization with 10 μl of 10% TDI in ethyl 
acetate. Control rats were sensitized and provocated with ethyl acetate under the same 
procedure.
group 1
group 2
5 days 2 days 5 days 9 days
9 days5 days2 days5 days
5 days 2 days 5 days 9 days
ethyl acetate
TDI
water
SST
group 3
with 70% ice-cold ethanol, air-dried and dissolved in
20 μl of diethylpyrocarbonate-treated water. RNA
samples (8 μg) were reverse-transcribed to cDNA in
a 40 μl reaction volume in the presence of a first-
strand buffer [250 mM Tris-HCl, pH 8.3, at room tem-
perature containing 375 mM KCl, 15 mM MgCl2, and
0.8 mM of each of deoxyribonucleoside phosphates
(dNTPs), 40 μM oligo (dT) primers, 0.004 units of
RNase inhibitor, and 8 units of reverse transcriptase
(Superscript II, Invitrogen)]. After samples were in-
cubated at 37℃ for 60 minutes, 2 μl of 2 N NaOH was
added before they were further incubated at 65℃ for
30 minutes. Subsequently, 12.8 μl of 1 M Tris-HCl,
pH 8.0, was added before samples were heated at
95℃ for 10 minutes and then chilled to 4℃ for 5 min-
utes. TaqMan primers and probe were designed us-
ing Primer Express software (Applied Biosystems).
The sequences of the primers and probes used for
H1R, HDC, IL-4, IL-5, and IL-13 mRNA measurement
are listed in Table 1. The primers and probe of rodent
glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
Applied Biosystems) were used for the internal stan-
dard. The transcripts were utilized for a 40-cycle-3-
step PCR using the Gene Amp 7300 Sequence Detec-
tion System (Applied Biosystems) in 20 mM Tris, pH
8.4, containing 50 mM KCl, 3 mM MgCl2, 200 μM
dNTPs, 900 nM each of the primer, and 0.25 units of
Platinum Taq. Amplicon size and reaction specificity
were confirmed by agarose gel electrophoresis. The
identity of the PCR products was verified by sequenc-
ing using a genetic analysis system (Beckman CEQ
8000, Beckman Coulter, Fullerton CA, USA).
STATISTICAL ANALYSIS
The results are presented as means ± standard errors
(SE). Data were analyzed using GraphPad Prism soft-
ware (GraphPad Software, Inc., San Diego, CA). One-
way ANOVA followed by Dunnet’s multiple compari-
son test were used for statistical analysis. P values
less than 0.05 were considered to indicate a statisti-
cally significant difference.
RESULTS
NASAL ALLERGY LIKE BEHAVIOR
Intranasal application of TDI induced nasal allergic
symptoms. We counted the number of sneezes for 10
minutes immediately after provocation as a parameter
of allergy intensity. In TDI-sensitized rats, the total
number of sneezes was 29 ± 1.4 (Fig. 2). Pretreat-
ment of SST suspension significantly suppressed
sneezing (7.7 ± 2.7). Control rats sensitized and pro-
vocated with ethyl acetate failed to show any allergic
symptoms.
H1R GENE EXPRESSION
Allergic pathogenesis is mediated mainly through
H1R. This led us to monitor the effect of SST on H1R
mRNA. H1R mRNA expression significantly in-
creased after TDI provocation (3.19 ± 0.22) compared
to the control group (1.0 ± 0.13, Fig. 3A). Oral admini-
stration of SST prior to sensitization almost com-
pletely attenuated this up-regulation (1.06 ± 0.24).
HDC mRNA EXPRESSION
To examine whether SST has any effect on histamine
synthesizing enzymes, we investigated the effect of
SST suspension on HDC gene expression. Oral ad-
ministration of SST was able to significantly suppress
the elevation of HDC mRNA expression (2.16 ± 0.06)
compared to that of TDI-sensitized allergy model rats
(6.05 ± 0.38, Fig. 3B).
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Fig. 2 SST reduces number of sneezes in TDI-sensitized 
nasal alergy model rats. Rats were sensitized and provoca-
tion induced as described in the Methods section. SST was 
given oraly 1 hour before sensitization and provocation. The 
number of sneezes was measured for 10 minutes immedi-
ately after provocation. ＊P ＜ 0.01 compared with control; 
＊＊P＜0.01 compared with TDI (n＝4).
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Table 1 Primer and probe sequences used for real-time RT-PCR
SequencePrimer/probe name
5’ -TATGTGTCCGGGCTGCACT-3’Sense primerH1R
5’ -CGCCATGATAAAACCCAACTG-3’Anti sense primermRNA
FAM-CCGAGAGCGGAAGGCAGCCA-TAMRAProbe
5’ -GCAGCAAGGAAGAACAAAATCC-3’Sense primerHDC
5’ -CAACAAGACGAGCGTTCAGAGA-3’Antisense primermRNA
FAM-AAAGCGCATGAGCCCAATGCTGCTGAT-TAMRAProbe
5’ -CAGGGTGCTTCGCAAATTTTAC-3’Sense primerIL-4
5’ -CACCGAGAACCCCAGACTTG-3’Anti sense primermRNA
FAM-CCCACGTGATGTACCTCCGTGCTTG-TAMRAProbe
5’ -CAGTGGTGAAAGAGACCTTGATACAG-3’Sense primerIL-5
5’ -GAAGCCTCATCGTCTCATTGC-3’Anti sense primermRNA
FAM-TGTCACTCACCGAGCTCTGTTGACG-TAMRAProbe
For measuring IL-13 mRNA, primer probe kit from Applied Biosystems (Rn00587615-A1 1113) was used.
EFFECT OF SST ON TDI-INDUCED IL-4, IL-5 AND
IL-13 mRNA ELEVATION IN RAT NASAL MU-
COSA
As Th2-cytokines play an important role in allergic
hyperresponses, we investigated the effect of SST on
the elevation of IL-4, IL-5 and IL-13 mRNA in nasal
mucosa of TDI-sensitized rats. Real-time RT-PCR
analysis showed that SST suppressed IL-4 mRNA sig-
nificantly (2.5 ± 0.30, Fig. 4A) compared to that of
TDI-sensitized allergic rats (5.5 ± 0.76), and almost
completely suppressed the expression of IL-5 mRNA
(1.37 ± 0.46, Fig. 4B). However, SST failed to show
any significant effect on IL-13 mRNA expression (Fig.
4C).
DISCUSSION
SST has been used for treating allergic diseases for a
long time in Asian countries. Previous studies demon-
strated the various pharmacological evidence behind
the anti-allergic effect of SST including the decrease
in antigen-induced eosinophil infiltration in guinea
pigs,21 suppression of allergen-induced bronchial in-
flammation in mite-sensitized mice,24 and decrease in
serum IgE level in allergic rhinitis patients.23,30 The
primary objective of this study was to evaluate the ef-
fect of SST on the gene expression of 2 important pa-
rameters in histamine signaling responsible for aller-
gic pathogenesis, i.e. H1R mRNA and HDC mRNA.
We also investigated the role of SST in the expres-
sion level of the Th2-cytokines, as histamine signal-
ing is closely related with Th2-cytokine signaling.
For this purpose, we used rats sensitized with TDI
as subjects in this study. Allergic rhinitis is an IgE
mediated disease and is distinct from other rhinitis.31
In more than 90% of patients, the allergens responsi-
ble for the cause of disease could be clarified. Never-
theless, since rhinitis caused by TDI is a non-IgE me-
diated disease,30 nasal symptoms and pathogenesis
observed in TDI-sensitized rats could be different.
However, intranasal application of TDI caused the
neuropeptide-mediated release of histamine from
mast cells in the nasal mucosa and led to the develop-
ment of nasal allergy-like symptoms such as sneezing
and water rhinorrhea in TDI-sensitized guinea pigs.14
In this respect, these TDI-induced nasal allergy-like
symptoms are similar to those observed in allergic
rhinitis patients. In addition to the nasal allergy-like
symptoms, TDI-sensitized rats exhibit many of the
characteristical features of allergic rhinitis in humans
including infiltration of eosinophils and mast cells,32
increase in the level of cytokines,17-20 elevation of
H1R mRNA and protein level,15 increase in HDC
mRNA level, and HDC activity and histamine con-
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Fig. 3 SST blocks TDI-induced up-regulation of H1R mRNA (A) and HDC mRNA (B). Rats were 
sensitized and provocated as described in the Methods section. SST was given oraly 1 hour be-
fore sensitization and provocation. Rats were sacrificed 4 hours after the TDI-provocation and the 
mRNA levels of H1R (A) and HDC (B) in the nasal mucosa were determined by quantitative real-
time RT-PCR. Data were normalized by rodent GAPDH mRNA and expressed as mean± stan-
dard eror (SE). ＊P＜0.01 compared with control; ＊＊P＜0.01 compared with TDI (n＝4).
0
1
2
3
4
H
1R
 m
R
N
A
/G
A
P
D
H
 m
R
N
A
0
2
4
6
8
H
D
C
 m
R
N
A
/G
A
P
D
H
 m
R
N
A
＊＊
＊
＊＊
＊
(A)
Control TDI SST Control TDI SST
(B)
Fig. 4 SST suppresses the TDI-induced IL-4 (A) and IL-5 (B) but not IL-13 mRNA elevations in TDI-sensitized alergy 
model rats. Rats were sensitized and provocated as described in the Methods section. SST was given oraly 1 hour before 
sensitization and provocation. Rats were sacrificed 4 hours after provocation and the mRNA levels of IL-4 (A), IL-5 (B), and 
IL-13 (C) in the nasal mucosa were determined by quantitative real-time RT-PCR. Data were normalized by rodent GAPDH 
mRNA and expressed as mean ± standard eror (SE). ＊P＜0.01 compared with control; ＊＊P＜0.01 compared with TDI
 (n＝4).
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tent,16 although neuropeptide, not IgE, triggered his-
tamine release in TDI-sensitized animals. Accord-
ingly it is difficult to differentiate between immu-
nological sensitization and irritation by low molecular
weight chemicals such as TDI and it is likely that the
underlying mechanisms driving TDI-induced rhinitis
share similarities with allergic rhinitis caused by
ubiquitous airborne protein allergens.
Pre-treatment with SST suppressed sneezing (Fig.
2). This finding corroborates the results of our previ-
ous studies that showed the trigger of such behaviors
after TDI stimulation.16,33 Nasal allergy-like behaviors
during the 10 minutes following provocation was
studied to examine the effect of SST in the early
phase which is derived from the release of preformed
histamine during the sensitization process. We did
not investigate the eosinophil infiltration in this study.
However, Irifune has reported on infiltration of
eosinophil and mast cells in tissue following TDI-
provocation in TDI-sensitized guinea-pigs.32 We have
observed a similar eosinophil infiltration following
TDI-provocation in TDI-sensitized rats (unpublished
observation). Thus, the suppressive effect of SST on
allergic symptoms also shows its effect in the induc-
tion phase.
Previously, we demonstrated that H1R is the key
factor for histamine signaling involved in allergic re-
sponses.15 In TDI-sensitized rats, neurogenic inflam-
mation caused the release of histamine from mast
cells in the nasal mucosa in IgE-independent man-
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ner30 and lead to the development of nasal hypersen-
sitivity.34 Pretreatment with d-chlorpheniramine sig-
nificantly reduced TDI-induced nasal hypersensitivity
behavior.35,36 Many other studies have also shown
the involvement of H1R in the pathogenesis of allergy
and high efficacy of H1R antagonists in controlling
nasal hypersensitivity symptoms in the elicitingef-
fecter phase of nasal allergy.33,37-39 Our study demon-
strated that the SST pre-treated group showed a sig-
nificant repression of TDI-induced H1R mRNA up-
regulation in rat nasal mucosa (Fig. 3A). This result
may contradict the findings of Sakaguchi et al. who
reported no effect of SST on [3H] mepyramine bind-
ing activity in guinea pig cerebral cortex21 and lung
and rat brain.28 They dissolved SST in distilled water
and administrated it orally. We, on the other hand,
created an extract of SST with hot water. As SST con-
sists of Pineliale Tuber (22.2%) and 11.1% of each of
Glycyrrhizae Radix, Cinnamomi Cortex, Schisandrae
Fructus, Asiasari Radix, Paeoniae Radix, Ephedrae
Herba, and Zingiberis sciccatum Rhizoma, hot water
extraction may have caused some changes in the in-
gredients. This may explain the conflict between our
results. Sakaguchi et al. also administrated SST to
animals for 1 week, while we treated rats with the
SST extract for 3 weeks. We have found that a 3-week
treatment of epinastine is more effective on the sup-
pression of H1R gene expression than a 1-week treat-
ment (unpublished data). Therefore it is possible that
this difference in duration of drug treatment can re-
sult in a different level of H1R gene expression.
HDC is the sole enzyme for the biosynthesis of his-
tamine.40 In this study, the expression of HDC mRNA
in the nasal mucosa significantly increased after TDI
provocation in TDI-sensitized rats (Fig. 3B). This
finding is in line with studies in which the HDC
mRNA level increased in patients with allergic rhinitis
and bronchial asthma.41,42 We examined the effect of
SST on this up-regulation of HDC gene expression in
TDI-sensitized rats. Our result demonstrated that
SST significantly suppresses the increase of HDC
mRNA expression (Fig. 3B). Since pretreatment of
SST also suppressed TDI-induced nasal allergy-like
behaviors, it is suggested that the SST reduced nasal
hypersensitivity by its inhibitory effect on the up-
regulation of HDC mRNA expression thereby sup-
pressing histamine synthesis. This result indirectly
supports the finding of Sakaguchi et al. showing the
suppression of histamine release from rat peritoneal
mast cells.21
Cytokines also play an important role in allergic
pathogenesis. Allergic diseases are associated with
an increase in the number of Th2 cells and Th2 cy-
tokines and a decrease in the number of Th1 cells
and Th1 cytokines. Th2 cytokines such as IL-4, IL-5,
IL-9 and IL-13 are involved in the initiation and main-
tenance of the allergic inflammation by promoting
eosinophil infiltration and IgE responses.5-9 In TDI-
sensitized animals, it has been reported that TDI
treatment increases not only Th2 cytokines including
IL-4, IL-5, and IL-13 but also Th1 cytokines such as
IFN-γ, therefore the inflammation induced by TDI is
associated with a mixed Th1Th2 immune re-
sponse.48 Johnson et al. have also shown that the in-
flammation and gene expression changes caused by
TDI-exposure were isolated to the upper airways and
that the lower airways showed no evidence of inflam-
mation. In addition, the changes observed in the na-
sal mucosa were most likely due to local antigen rec-
ognition, processing, and presentation to effector
cells at the site of exposure.48 In the present study,
we found that SST significantly suppressed the up-
regulation of IL-4 and IL-5 but had no effect on IL-13
mRNA in the nasal mucosa of TDI-sensitized allergy
model rats (Fig. 4). This finding is parallel to the re-
ports describing the suppressive effect of SST on Th2
differentiation in CD4+ T cells in mice,25-27,42,43 al-
though some contradicting effects of SST on Th2 cy-
tokines have been reported in allergic patients.23,30
IL-4 shares many biological properties with IL-13 and
the redundancy between two cytokines is explained
by their sharing of the common receptor subunit.44
However, many reports have suggested that IL-4 and
IL-13 may be under differential regulation under
some level of independent regulation.45,46 Ghaffar et
al. showed that the percentage of the IL-13 mRNA
positive cells co-expressing the IL-4 mRNA was 66.6 ±
10.5%, although 100% of the IL-4 mRNA positive cells
expressed IL-13 transcript.47 It was also reported that
the expression pattern of IL-13 was different from
that of IL-4 in the nasal mucosa of TDI-induced aller-
gic rhinitis mice.48 Therefore, it is possible that SST
showed the opposite effect on IL-4 and IL-13 gene ex-
pression in TDI-sensitized rats.
Increasing experimental evidences suggest the ex-
istence of the histamine-cytokine network in allergic
inflammation, in which histamine influences the ex-
pression and actions of several cytokines and some
cytokines modulate the production and release of his-
tamine.10-13,20 It has been reported that pre-treatment
of IL-4 primes for the release of histamine,
prostaglandins, leukotrienes, and cytokines in re-
sponse to FcεRI.49,50 On the contrary, reports have in-
dicated that histamine modulates the release of IL-4
and IFN-γ from T cells51 and induces the release of
IL-5.52 Our data suggest that pre-treatment with SST
suppresses histamine-cytokine network.
In conclusion, pre-treatment with SST improves
TDI-induced nasal allergic symptoms by suppressing
TDI-induced elevation of H1R and HDC gene expres-
sion, the key components of histamine signaling in
rat nasal mucosa, in addition to gene expression of
some Th2 cytokines including IL-4 and IL-5.
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